BiotechTube
CCRP Therapeutics

CCRP Therapeutics

Munich, Germany· Est.
ccrp-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CCRP Therapeutics is a Munich-based, preclinical-stage biotech developing first-in-class small molecule inhibitors of the renin/prorenin receptor (RERBs). Originating from the prestigious Charité hospital, the company is pursuing a dual therapeutic strategy targeting multiple solid tumors and chronic end-organ damage, representing a novel approach in both oncology and cardiometabolic diseases. As a private, early-stage spin-off, its success hinges on validating its unique mechanism and advancing its lead candidates into clinical trials.

OncologyCardiometabolic Diseases

Technology Platform

Discovery platform for small molecule Renin/Prorenin Receptor Blockers (RERBs) targeting the (pro)renin receptor (PRR) to inhibit pathways critical in cancer proliferation and end-organ damage.

Opportunities

The company targets large, high-need markets in oncology and chronic disease complications with a first-in-class mechanism.
Its dual focus allows for platform efficiency and multiple value inflection points.
Strong academic origins provide scientific credibility and potential for non-dilutive grant funding.

Risk Factors

High risk associated with novel target validation; clinical efficacy of PRR inhibition is unproven.
As a preclinical, private company, it faces significant financing risk and operational challenges in transitioning from academia.
Intense competition in both therapeutic areas from large, well-funded entities.

Competitive Landscape

In oncology, competitors include all major pharma/biotech companies with targeted therapies and immuno-oncology agents. In end-organ damage, competition is from established drug classes (SGLT2i, GLP-1 RA, RAS inhibitors). CCRP's key differentiator is its novel target; there are no known direct competitors developing small molecule PRR blockers clinically.

More companies in Small Molecule Drugs →More companies in Germany →